The Global Rare Disease Clinical Trials Market Size is valued at 12.28 billion in 2023 and is predicted to reach 25.05 billion by the year 2031 at a 9.39% CAGR during the forecast period for 2024-2031.
The lack of medications available to treat rare diseases, advancements in personalized medicine, and cell and gene therapies, which are opening up new pathways for new treatments for rare diseases, are a few of the causes contributing to this expansion. Also, a rise in financing for clinical trials for rare diseases from pharmaceutical, biotech, and non-profit groups is driving market expansion.
The COVID-19 outbreak significantly impacted the capacity to perform clinical trials. The pandemic forced the suspension and postponement of numerous clinical trials for uncommon diseases and the delay of participant recruitment. Due to this, new medications and therapies created for the treatment of rare diseases took longer. However, by the second half of 2020, clinical studies of rare illnesses had resumed, and they have now begun. This is likely to sustain the industry throughout the post-pandemic phase.
Recent Developments:
- In January 2023, Genethon, an R&D company, began a crucial clinical trial for the use of gene therapy to treat Crigler-Najjar Syndrome. Crigler-Najjar syndrome is a rare genetic liver disease marked by abnormally elevated bilirubin levels in the blood. (hyperbilirubinemia).
- In November 2022, The Biologics License Application (BLA) for PRX-102 (pegunigalsidasealfa) for the treatment of adult patients with Fabry disease was re-submitted to the US Food and Drug Administration (FDA) by ProtalixBiotherapeutics Inc. and Chiesi Global Rare Diseases.
Competitive Landscape:
Some of the Rare Disease Clinical Trials market players are:
- Takeda Pharmaceutical Company;
- Hoffmann-La Roche Ltd.;
- Pfizer, Inc.;
- AstraZeneca;
- Novartis AG;
- LabCorp;
- IQVIA, Inc.;
- Charles River Laboratories;
- Icon PLC;
- Parexel International Corporation
Market Segmentation:
The Rare Disease Clinical Trials market is segmented by therapeutic area, phase, and sponsor. Based on the therapeutic site, the market is segmented as Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Disease, Genetic Disorders, Autoimmune and Inflammation, Hematologic Disorders, Musculoskeletal Disorders, and Others. By phase the market is segmented into Phase I, II, III, and IV. By drug, the market is segmented as OTC and Rx. By sponsor, the market is segmented as Pharmaceutical & Biopharmaceutical Companies, Non-profit Organizations, and Others.
Based On Phase, Phase II Is Accounted As A Significant Contributor In The Rare Disease Clinical Trials Market
The majority belonged to Phase II. Phase II studies are carried out in two stages; the first stage combines efficacy and dose range exploration; the second stage finalises the dose. Between 100 to 300 people are enrolled in Phase II clinical trials. The phase II category had the most registered clinical studies as of November 2022. On the ClinicalTrial.gov portal, 72,522 research had been registered as of November 2022. The large number of Phase II clinical studies is assisting in the segment's expansion.
Oncology Segment Witness Growth At A Rapid Rate
The largest share belonged to the oncology sector. Some of the main drivers of the segment's growth are the high number of cancer drug approvals for rare diseases, the rise in cancer clinical trials, and the increased interest among scientists in developing effective treatments for uncommon malignancies. As an illustration, the USFDA authorised the immunotherapy medication atezolizumab (Tecentriq) in January 2023 for use in patients with advanced alveolar soft part sarcoma (ASPS).
The North America Rare Disease Clinical Trials Market Holds Significant Revenue Share In The Region
Due to advantageous reimbursement rules, increased spending on orphan pharmaceuticals for the treatment of rare diseases, and the existence of prominent market participants who encouraged the creation of novel products, North America accounted for the most significant revenue share. Moreover, the U.S. FDA can approve medications used to treat critical disorders quickly. The FDA's drug approval procedure is streamlined by the Accelerated Approval Rules, which permit a treatment used to treat a critical ailment to be approved using a surrogate end-point. All of these elements are anticipated to boost the North American market.
Rare Disease Clinical Trials Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 12.28 Bn |
|
Revenue forecast in 2031 |
USD 25.50 Bn |
|
Growth rate CAGR |
CAGR of 9.39% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Therapeutic Area, Phase, And Sponsor |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Takeda Pharmaceutical Company; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Novartis AG; LabCorp; IQVIA, Inc.; Charles River Laboratories; Icon PLC; Parexel International Corporation. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
